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Objective: The goal of this study was to test the ability of an injectable self-assembling peptide (KLD)
hydrogel with or without chondrogenic factors (CF) and allogeneic bone marrow stromal cells (BMSCs) to
stimulate cartilage regeneration in a full-thickness, critically-sized, rabbit cartilage defect model in vivo. We
used CF treatments to test the hypotheses that CF would stimulate chondrogenesis and matrix production
by cells migrating into acellular KLD (KLDþ CF) or by BMSCs delivered in KLD (KLDþ CFþ BMSCs).
Design: Three groups were tested against contralateral untreated controls: KLD, KLDþ CF, and KLDþ CFþ
BMSCs, n¼ 6e7. Transforming growth factor-b1 (TGF-b1), dexamethasone, and insulin-like growth
factor-1 (IGF-1) were used as CF pre-mixed with KLD and BMSCs before injection. Evaluations included
gross, histological, immunohistochemical and radiographic analyses.
Results: KLD without CF or BMSCs showed the greatest repair after 12 weeks with signiﬁcantly higher
Safranin-O, collagen II immunostaining, and cumulative histology scores than untreated contralateral
controls. KLDþ CF resulted in signiﬁcantly higher aggrecan immunostaining than untreated contralateral
controls. Including allogeneic BMSCsþ CF markedly reduced the quality of repair and increased osteo-
phyte formation compared to KLD-alone.
Conclusions: These data show that KLD can ﬁll full-thickness osteochondral defects in situ and improve
cartilage repair as shown by Safranin-O, collagen II immunostaining, and cumulative histology. In this
small animal model, the full-thickness critically-sized defect provided access to the marrow, similar in
concept to abrasion arthroplasty or spongialization in large animal models, and suggests that combining
KLD with these techniques may improve current practice.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Repair of articular cartilage injuries remains a challenge, despite the
development of surgical treatments such as microfracture, abrasion
arthroplasty, and spongialization, which are used with the goal of
recruiting marrow-derived cells by penetration of the subchondral
bone. While these techniques promote increased short-term healing,
long-term repair still consists of mechanically-inferior ﬁbrocartilage1.
Recent research has focused on tissue engineering strategies usingDavid D Frisbie, CSU Ortho-
ine and Biomedical Sciences,
USA. Tel: 970-297-4555; Fax:
e).
s Research Society International. Pscaffolds to improve cartilage repair and regeneration. In particular,
hydrogels made from materials such as chitosan-glycerol phosphate2,
polyethylene glycol (PEG)3, ﬁbrin4, polyglycolic-co-lactic acid (PLGA)5,
and collagen6 have been explored with the goal of improving the
accumulation of extracellular matrix produced by cells (e.g., bone
marrowstromalcells (BMSCs))migrating intothescaffold frommarrow.
Stimulation of BMSC chondrogenesis in vitro and in vivo has
received much attention. In vitro studies have shown that trans-
forming growth factor-b1 (TGF-b1), dexamethasone, and insulin-
like growth factor-1 (IGF-1) promote chondrogenesis of BMSCs7e11,
and methods for delivering these chondrogenic factors (CF) have
been developed, often in conjunction with scaffolds12e15. There
have been a number of in vivo studies performed delivering IGF-
14,16, TGF-b11,17,18, or the combination of IGF-1 and TGF-b113,16,19
to cartilage defects in order to stimulate chondrogenesis ofublished by Elsevier Ltd. All rights reserved.
Table I
Treatment groups with amounts delivered per animal
Group n KLD
(mg)
b-KLD
(mg)
TGF-b1
(ng)
b-IGF
(ng)
Streptavidin
(ng)
Dex
(ng)
BMSCs
(x103)
1 (KLD) 6 48 0.48 0 0 0 0 0
2 (KLDþ CF) 6 48 0.48 1.4 4.1 30.7 0.6 0
3 (KLDþ CFþ
BMSCs)
7 48 0.48 1.4 4.1 30.7 0.6 150
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incorporated dexamethasone.
The hypothesis that delivery of exogenous BMSCs to the joint
can enhance cartilage regeneration has prompted the exploration
of a wide variety of growth factor and scaffold combinations to
stimulate BMSC chondrogenesis1,20,21. In vivo studies have
attempted to deliver BMSCs alone22,23, BMSCs encapsulated in
scaffolds24e26, and BMSCs encapsulated in scaffolds with the
inclusion of TGF-b127e30. Despite the in vitro promise shown by
three dimensional (3D)-cultured BMSCs, most long-term in vivo
treatments with BMSCs have resulted in sub-optimal cartilage
repair tissue20,22,24,26. Improving BMSC chondrogenesis in vivo is
likely dependent on several factors that are not well understood,
including cell delivery, microenvironment, and a combination of
pro-chondrogenic longitudinal signaling. In addition, an ideal
clinical approach would minimize or obviate the in vitro culture
duration and be performed with a single arthroscopic procedure.
Recent studies have shown that hydrogels made from the self-
assembling peptide sequences (RADA)4 and (KLDL)3 (hereafter
referred to as KLD) can maintain the chondrocyte phenotype31 and
stimulate chondrogenesis of BMSCs in vitro32e34. These hydrogels
have the ability to rapidly assemble when exposed to physiological
pH and ionic strength35 and have pore sizes in the range of
100e500 nm36. These synthetic peptides have been used in vivo
without immunogenic reaction37. Furthermore, TGF-b1 has been
shown to adsorb to KLD when pre-mixed with the peptide solution
prior to assembly, resulting in extended delivery of TGF-b1 to
BMSCs and stimulating chondrogenesis in vitro, promoting sGAG
production and accumulation comparable to continuous medium
supplementation of TGF-b1 over 21 days38. In addition, including
dexamethasone with TGF-b1 in medium supplementation during
the in vitro culture of BMSCs in RADA results in less catabolic
cleavage of aggrecan compared to culture with TGF-b1 alone39.
Finally, IGF-1 can be tethered to peptide scaffolds via bio-
tinestreptavidin bonds; this tethered IGF-1 has been shown to
remain biologically active and to promote cell survival in rat car-
diomyocytes over 28 days37.
The goal of this study was to test the ability of an injectable KLD
hydrogel with or without BMSCs and CF to stimulate cartilage
regeneration in vivo in a critically-sized rabbit full-thickness carti-
lage defect model. This model provides access to the marrow,
analogous to abrasion arthroplasty or spongialization in large
animal models. We used CF treatments (IGF-1, TGF-b1, and dexa-
methasone) to test the hypotheses that CF would stimulate chon-
drogenesis and matrix production (1) by cells migrating into
acellular KLD and (2) by P2 passaged allogeneic BMSCs delivered in
KLD. IGF-1 was tethered to the peptide with a biotinestreptavidin
bond37 to stimulate long-term production of cartilage ECM, while
TGF-b1 and dexamethasone were pre-mixed with KLD prior to
BMSC encapsulation to stimulate chondrogenesis and initial matrix
production. A 12-week timepoint enabled evaluation of mid-term
beneﬁts of the treatment compared to contralateral untreated
defects.
Methods
Materials
KLD peptide with the sequence AcN-(KLDL)3-CNH2 was
synthesized by the MIT Biopolymers Laboratory (Cambridge, MA)
using an ABI Model 433A peptide synthesizer with FMOC protec-
tion. Human recombinant TGF-b1 (R&D Systems, Inc., Minneapolis,
MN), dexamethasone (SigmaeAldrich, St. Louis, MO), sucrose
(SigmaeAldrich), biotinylated-IGF-1 (bIGF-1) (immunological and
biochemical testsystems GmbH, Reutlingen Germany), streptavidin(Pierce Biotechnology, Inc, Rockford, IL), biotinylated-KLD (biotin-
(aminocaproic acid)3-(KLDL)3 or b-KLD) (MIT Biopolymers Labo-
ratory), FBS (Invitrogen, Carlsbad, CA), and FGF-2 (R&D Systems,
Inc.) were purchased and used as described.Cell isolation
Bone marrow was harvested and pooled from four rabbits used
for an initial pilot study, and BMSCs were isolated as previously
described34. BMSCs were selected via differential adhesion to
plastic and expanded two passages in alpha MEMwith 10% FBS and
2 ng/mL FGF-2, 10 mM HEPES, and PSA (100 U/mL penicillin,
100 mg/mL streptomycin, and 250 ng/mL amphotericin), resulting
in a total of approximately four population doublings. Each passage
was conducted by seeding at a concentration of 12103 BMSCs/
cm2 and incubating for 2 days to allow BMSCs to grow to w75%
conﬂuence.In vivo study design
All procedures were approved by the Animal Care and Use
Committees at Colorado State University and Massachusetts Insti-
tute of Technology. Twenty skeletally mature, retired, female
breeder New Zealand White rabbits (average age 11 months and
body weight 4.7 kg) were used for this study (Myrtle’s Rabbitry,
Thompson Station, TN). One rabbit died during the study due to
neurological problems post-surgery and was not included in the
analysis. The n values shown in Table I do not reﬂect this animal.
Three different groups were tested against contralateral, untreated,
empty controls: (1) KLD, (2) KLDþCF, and (3) KLDþ CFþ BMSCs
(Table I). For all groups, KLDwas resuspended in 10% sterile sucrose,
and the ﬁnal KLD concentration was kept constant at 3.2 mg/mL.
For groups 2 and 3, KLD peptide (48 mg) was pre-mixed with a CF
mixture consisting of 1.4 ng TGF-b1, 0.6 ng dexamethasone, 4.1 ng
bIGF-1, 30.7 ng streptavidin, and 0.48 mg b-KLD. For group 3,
150103 BMSCs were encapsulated in the KLD/CF mixture34.
Encapsulation of BMSCs in vitro in this manner resulted in 80e90%
viability. In vitro studies indicated that this amount of TGF-b1
would result in a concentration of TGF-b1 inside the scaffold
sufﬁcient to stimulate chondrogenesis38. At the same time, if all of
the TGF-b1 were to be released from the scaffold at once into the
joint space in vivo, it would amount to approximately 1 ng/mL
concentration in the joint space (1.4 ng/1.4 mL joint space
volume40), compared to the native concentration of 52.3 pg/mL
found in adult rabbits40. Streptavidin and bIGF-1 were mixed at
a 1:1 molar ratio in order to achieve, on average, binding of one
bIGF-1 to each streptavidin allowing streptavidin to still bind b-KLD
(in 100 molar excess of streptavidin and bIGF-1 to ensure
homogeneous distribution of IGF-1 throughout the gel). The ability
of this tethering to occur using these molar ratios has been shown
in vitro and in vivo37. The amount of bIGF-1 tethered was chosen to
provide a local concentration of 300 ng/mL inside the scaffold,
which is above the threshold shown to be sufﬁcient for chon-
drocyte stimulation of proteoglycan synthesis in vivo41.
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All surgical procedures were performed under inhalation
general anesthesia. A medial-parapatellar arthrotomy approach
to the femoropatellar joint was performed, and the patella was
luxated laterally. A 3mm-diam 2mm-deep full-thickness,
critically-sized defect was created in the central region of the
femoral trochlear groove (Fig. 1). Direct pressure was applied
with a surgical sponge to ensure all bleeding was stopped prior
to application of the peptide, which was delivered as a liquid.
Defects were ﬁlled with designated treatments (15 mL volume)
or left untreated, as dictated by group assignment. The liquid
peptide suspension could easily be seen ﬁlling the defect, and
defects were ﬁlled until visually full. At this time, Lactated
Ringer’s Solution was added to the joint periphery to gently ﬁll
the joint and cause polymerization of the peptide, which was
visually inspected to ensure retention of the implant. Dorsal-
caudal and lateral-medial 90 radiographs of each stiﬂe joint
were obtained immediately after surgery. At 12 weeks, rabbits
were euthanized with pentobarbital after sedation. Post-
surgical radiographic views were repeated following
euthanasia.Fig. 1. Gross necropsy photographs of treated and untreaGross pathologic observations of joints
The limbs and joints were examined and graded by a blinded
observer (DDF) unaware of treatment group (Table II). For the
musclewastagemeasurement, the limbs were shaved and a ﬂexible
tapemeasurewas used in a similar anatomic location of the stiﬂe to
make this assessment. This scoring system was chosen in order to
compare to other studies performed by Frisbie et al.6
Synovial membrane histology
Synovial membrane was harvested and placed in neutral-buff-
ered 10% formalin, embedded in parafﬁn, 5-mm sections created
and stained with hematoxylin and eosin (H&E). Sections were
evaluated blindly (DDF) for cellular inﬁltration, vascularity, intimal
hyperplasia, subintimal edema and subintimal ﬁbrosis on a scale of
0e4 (0¼ none, 1¼ slight, 2¼mild, 3¼moderate, 4¼ severe)42.
Articular cartilage histology and immunohistochemistry
At the time of necropsy, the circular defect area was cut in half
with an Exakt bandsaw. The medial half of the repair tissue withted joints in KLD, KLDþ CF, and KLDþ CFþ BMSCs.
Table II
Gross observations scoring system
Feature Score
I. Joint observation
Normal appearance 0
Slight inﬂammation 1
Moderate inﬂammation 2
Severe inﬂammation 3
II. Incision appearance
Normal appearance 0
Slight inﬂammation 1
Moderate inﬂammation 2
Severe inﬂammation 3
Slight dehiscence (incision basically intact) 4
Marked dehiscence (requires intervention) 5
Active infection 6
Healing infections 7
III. Muscle wastage at the time of necropsy in treated vs untreated limbs
Circumferential measurement at the proximal aspect of the patella (cm)
IV. Angle of stiﬂe: change in normal angle (if any)
None, within normal limits 0
Abnormal 1
V. Inﬂammation/swelling
None, within normal limits 0
Abnormal 1
VI. Trauma/damage
None, within normal limits 0
Abnormal 1
VII. Infection/discharge
None, within normal limits 0
Abnormal 1
VIII. Presence of osteophytes and other osteoarthritic changes
None, within normal limits 0
Abnormal 1
IX. Articular surface integrity, contour, and congruity
Normal 0
Abnormal 1
X. Presence of loose bodies in synovial ﬂuid
None, within normal limits 0
Abnormal 1
XI. Injury to apposing articular surface
None, within normal limits 0
Abnormal 1
XII. Synovial membrane appearance
Normal 0
Slight 1
Mild 2
Moderate 3
Severe 4
XIII. Cartilage attachment
This category describes on average the defect repair tissue attachment with the
surrounding normal cartilage.
Possible responses were:
Normal attachment 0
Moderate attachment 1
Mild attachment 2
Slight attachment 3
No attachment 4
XIV. Bone attachment
This category describes the ﬁrmness of the repair tissue attachment to the bone
at the base of the defect.
Possible responses were:
Similar to surrounding cartilage 0
Slightly-soft-vs-surrounding cartilage 1
Mildly soft-vs-surrounding cartilage 2
Moderately soft-vs-surrounding cartilage 3
Marked softening-vs-surrounding cartilage 4
(continued on next page)
Table II (continued )
Feature Score
XV. Firmness
This category describes on average the ﬁrmness of the repair tissue to normal
surrounding articular cartilage.
Possible responses were:
Similar compared to surrounding cartilage 0
Slightly-soft compared to surrounding cartilage 1
Mildly soft compared to surrounding cartilage 2
Moderately soft compared to surrounding cartilage 3
Marked softening compared to surrounding cartilage 4
XVI. Blood
This category describes the presence or absence of hemorrhage associated with
the defect area or its periphery.
Possible responses were:
Fresh blood, active hemorrhage at time of surgery 1
Old blood, no active hemorrhage at time of surgery 2
No blood visualized at time of surgery 3
XVII. Shape
This category describes the margin of the defect as it relates to the original
geometry at time 0 (creation). Possible responses were:
No apparent change in damage tissue beyond defect 0
Degeneration in tissue beyond defect 1
XVIII. Grade (Overall quality of repair)
This category describes the overall subjective evaluation of the repair tissue by
the evaluator. Criteria used to determine the grade were:
(1) Attachment of repair tissue to the surrounding normal articular cartilage
(2) Level (height) and undulation of the repair tissue surface as compared to the
surrounding normal articular cartilage (3) Color of the repair tissue, where
white homogenous tissue without a ﬁbrous like appearance is used as the “gold
standard.”
Tissue not present to grade 0
Poor 1
Fair 2
Good 3
Excellent 4
XIX. Level
This category describes the level of repair tissue ﬁlling in association with the
surrounding normal articular cartilage.
Possible responses in relation to the surrounding normal articular cartilage
were:
Mildly recessed 1
Slightly recessed 2
Leveled 3
Slightly elevated 4
Mildly elevated 5
Moderately elevated 6
XX. Color
This category describes the color of the repair tissue.
When repair tissue is characterized by two colors, the predominate color is
indicated ﬁrst. Possible responses were:
Red 1
White/red 2
Yellow 3
Yellow/white 4
White/yellow 5
White 6
XXI. Surface
This category describes the relative undulation of the repair tissue surface.
Possible responses were:
Non-undulating 1
Slightly undulating 2
Mildly undulating 3
Moderately undulating 4
XXII. Area
Percent of surface area ﬁlled in defect (0e100%)
XXIII. Volume
Percent of volume ﬁlled in defect (0e100%)
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formalin for histology, and the lateral half was embedded in OCT
and then ﬂash frozen for immunohistochemistry.
For histology, the ﬁxed tissue was decalciﬁed, embedded in
parafﬁn, sectioned at 5 mm, and stained with either H&E or
Safranin-O, fast green (SOFG) (ThermoScientiﬁc/Shandon VeriStain
Gemini ES stainer) for proteoglycan visualization. Sections stained
with H&E were evaluated blindly (DDF) using a modiﬁed O’Driscoll
scoring system6,43 (Table III) with a maximum cumulative histology
score of 28 and a higher score indicating a repair more like native
cartilage. Sections stained with SOFG were evaluated blindly (DDF)Table III
Modiﬁed O'Driscoll histological scoring system
Feature Score
I. Nature of the repair tissue
Some ﬁbrocartilage, mostly non-chondrocytic cells 0
Mostly ﬁbrocartilage 1
Mixed hyaline and ﬁbrocartilage 2
Mostly hyaline cartilage 3
Hyaline cartilage 4
II. Surface regularity
Severe disruption, including ﬁbrillation 0
Fissures 1
Superﬁcial horizontal lamination 2
Smooth and intact 3
III. Structural integrity (morphologic zone reconstitution)
Severe disintegration 0
Slight disruption, including cysts 1
Normal 2
IV. Thickness
0e50% of normal cartilage 0
50e100% of normal cartilage 1
100% of normal adjacent cartilage 2
V. Bonding to adjacent cartilage
Not Bonded 0
Bonded at one end or partially at both ends 1
Bonded at both ends of graft 2
VI. Hypocellularity
Moderate hypocellularity 0
Slight hypocellularity 1
Normal cellularity 2
VII. Chondrocyte clustering
25e100% of the cells 0
<25% of the cells 1
No clusters 2
VIII. Freedom from degenerative changes in adjacent cartilage
Severe hypocellularity, poor or no staining 0
Mild or moderate hypocellularity, slight staining 1
Normal cellularity, mild clusters, moderate staining 2
Normal cellularity, no clusters, normal staining 3
IX. Reconstitution of subchondral bone
No Subchondral bone reconstitution 0
Minimal subchondral bone reconstitution 1
Reduced subchondral bone reconstitution 2
Normal 3
X. Inﬂammatory response in subchondral bone region
Severe 0
Moderate 1
None/mild 2
XI. Safranin-O staining
None 0
Slight 1
Moderate 2
Normal 3
XII. Cumulative histology score (sum of above scores) 0e28for intensity of staining on a scale of 0e3 (Table III) and were
included in the cumulative histology score.
For immunohistochemical analyses, frozen tissue was sectioned
at 8 mm. Each section was incubated in 0.25 U/mL chondroitinase
ABC (SigmaeAldrich) for 15 min before incubation in primary
antibody solution (Collagen I (1:10) #M-38-s and II (undiluted) #
II-II6B3-s, Hybridoma Bank Aggrecan (1:100, Alexis Biochemicals)
#ALX-803-313; or rabbit IgG as control). Endogenous peroxidase
was blocked using 0.3% H2O2 in methanol. Sections were incubated
in goat anti-mouse HRP secondary antibody solution (1:500, Jack-
son Immunoresearch, West Grove, PA), stained with Vector Nova
RED (Vector Laboratories, Burlingame, CA) and counterstained with
Fast Green. Controls gave no signal. Non-calciﬁed tissues were
evaluated blindly (DDF) for the percentage of repair tissue stained
positive (0¼ no stain, 1¼1e25%, 2¼ 26e50%, 3¼ 51e75%,
4¼76e100%).
Radiographic analysis
Radiographs and photographs were taken of bone segments
from femoral sections. Radiographs were graded for presence of
lysis, bony proliferation, osteophyte presence, and patellar luxation,
and a total radiographic score was calculated by summing these
scores (maximum score of 16). All grading was done on a 0e4 scale
(0¼ none, 1¼ slight, 2¼mild, 3¼moderate, 4¼ severe)22,42.
Additionally, radiographs post-euthanasia were scored for healing
of the defect (0¼ no healing, 1¼ slight healing, 2¼mild bone
ﬁlling, 3¼ lesion is visible but difﬁcult to measure, 4¼ lesion is not
visible to measure), sclerosis around the defect, and other sclerosis
(0e4, none-severe). Sclerosis is deﬁned as the increase in density of
bone seen radiographically and was subjectively scored by MFB in
a blinded fashion.
Statistical analyses
Scores were evaluated for inter- and intra-group differences
using an ANOVA framework with PROC GLIMMIX (ﬁts generalized
linear mixed models) of SAS (Cary, NC)44 with rabbit as a random
variable. For all joint pathologic, histological, immunohistochem-
ical, and radiographic analyses, intra-group differences were
analyzed with treatment set as the main effect (one-way); differ-
ences among groups were analyzed using treatment and group as
main effects (two-way). Untreated controls were therefore
analyzed separately depending onwhat treatment the contralateral
joint received in order to account for possible systemic effects45.
When main or interaction effects had P-values that were consid-
ered signiﬁcant (P-value< 0.05) or a trend (0.05< P-value< 0.10),
individual comparisons were made using the least square means
procedure22. P-values presented in the text include which main
effect or interaction term they are referring to if quoted for
comparisons among groups. All data are presented as mean -
 standard error of the mean (SEM). Non-parametric analyses were
also performed when appropriate. The authors were able to reach
similar conclusions based on either analysis. Because the authors
feel many of the biological outcome parameters represent more of
a continuum rather than deﬁned categories, the parametric anal-
ysis of the data is presented.
Results
Radiographic analyses
Radiographic analyses pre-treatment did not show any sclerosis
in any of the rabbits. Treated defects post-treatment showed some
slight osteophyte formation (0.3 (0.0, 0.6), treated; 0.1 (0.2, 0.4),
Table IV
Gross scores. One-way P-values for within group comparisons are listed in the untreated columns. Two-way P-values for differences among groups are in a separate column (TXT¼ treatment, Group¼ group,
TXT*Group¼ interaction term). P-values are not shown when all the scores being compared are zero. Mean and conﬁdence intervals calculated during two-way analysis are shown
Gross scores KLD KLDþ CF KLDþ CFþ BMSCs Two-way P-values
Feature Treated n¼ 6 Untreated n¼ 6 Treated n¼ 6 Untreated n¼ 6 Treated n¼ 7 Untreated n¼ 7
I. Joint observation 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
II. Incision appearance 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
III. Muscle wastage at the time
of necropsy in treated
vs untreated limbs
(circumference in cm)
12.8 (12.2, 13.4) 12.4 (11.8, 13.0), P¼ 0.010 12.8 (12.2, 13.4) 12.7 (12.1, 13.3), P¼ 0.530 13.0 (12.5, 13.6) 12.9 (12.4, 13.5), P¼ 0.049 TXT: 0.001 Group: 0.553
TXT*Group: 0.032
IV. Angle of stiﬂe: change in
normal angle (if any)
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
V. Inﬂammation/swelling 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
VI. Trauma/damage 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
VII. Infection/discharge 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
VIII. Osteophytes and other
osteoarthritic changes
0.0 (0.3, 0.3) 0.0 (0.3, 0.3), P¼ 1.000 0.2 (0.2, 0.5) 0.2 (0.2, 0.5), P¼ 1.000 0.6 (0.3, 0.9) 0.6 (0.3, 0.9), P¼ 1.000 TXT: 1.000 Group: 0.029
TXT*Group: 1.000
IX. Articular surface integrity,
contour, and congruity
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
X. Presence of loose bodies
in synovial ﬂuid
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
XI. Injury to apposing
articular surface
0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
XII. Synovial membrane 0.5 (0.0, 1.0) 0.3 (0.1, 0.8), P¼ 0.611 0.2 (0.3, 0.6) 0.3 (0.1, 0.8), P¼ 0.562 0.1 (0.3, 0.6) 0.3 (0.1, 0.7), P¼ 0.356 TXT: 0.750 Group:
0.685 TXT*Group: 0.605
XIII. Cartilage attachment
to surrounding cartilage
0.7 (0.0, 1.4) 1.0 (0.3, 1.7), P¼ 0.530 0.5 (0.2, 1.2) 0.3 (0.4, 1.0), P¼ 0.611 0.4 (0.2, 1.1) 1.0 (0.3, 1.7), P¼ 0.172 TXT: 0.299 Group: 0.541
TXT*Group: 0.423
XIV. Bone attachment 0.3 (0.3, 1.0) 0.7 (0.0, 1.3), P¼ 0.363 0.7 (0.0, 1.3) 0.5 (0.1, 1.1), P¼ 0.695 0.3 (0.3, 0.9) 0.9 (0.3, 1.5), P¼ 0.030 TXT: 0.192 Group: 0.970
TXT*Group: 0.262
XV. Firmness 0.7 (0.1, 1.5) 0.8 (0.0, 1.6), P¼ 0.741 1.0 (0.2, 1.8) 0.5 (0.3, 1.3), P¼ 0.296 0.4 (0.3, 1.2) 1.0 (0.3, 1.7), P¼ 0.172 TXT: 0.750 Group: 0.995
TXT*Group: 0.222
XVI. Blood 3.0 (2.9, 3.1) 3.0 (2.9, 3.1), P¼ 1.000 3.0 (2.9, 3.1) 3.0 (2.9, 3.1), P¼ 1.000 3.0 (2.9, 3.1) 2.9 (2.7, 3.0), P¼ 0.356 TXT: 0.384 Group: 0.449
TXT*Group: 0.449
XVII. Shape 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0) 0 (0, 0)
XVIII. Grade (overall
quality of repair)
3.2 (2.3, 4.0) 2.2 (1.3, 3.0), P¼ 0.076 2.7 (1.8, 3.5) 2.8 (2.0, 3.7), P¼ 0.818 3.3 (2.5, 4.0) 2.4 (1.7, 3.2), P¼ 0.017 TXT: 0.061 Group: 0.896
TXT*Group: 0.220
XIX. Level 2.7 (2.0, 3.3) 2.0 (1.3, 2.7), P¼ 0.102 2.5 (1.8, 3.2) 2.3 (1.7, 3.0), P¼ 0.695 2.7 (2.1, 3.3) 2.3 (1.7, 2.9), P¼ 0.200 TXT: 0.050 Group: 0.897
TXT*Group: 0.613
XX. Color 5.8 (4.7, 6.9) 4.7 (3.6, 5.8), P¼ 0.126 4.8 (3.7, 5.9) 4.8 (3.7, 5.9), P¼ 1.000 5.9 (4.8, 6.9) 5.3 (4.3, 6.3), P¼ 0.231 TXT: 0.182 Group: 0.363
TXT*Group: 0.547
XXI. Surface 1.8 (1.2, 2.5) 2.2 (1.5, 2.8), P¼ 0.465 1.5 (0.8, 2.2) 2.0 (1.3, 2.7), P¼ 0.296 1.7 (1.1, 2.3) 2.0 (1.4, 2.6), P¼ 0.457 TXT: 0.127 Group: 0.753
TXT*Group: 0.925
XXII. Area 94.2 (80.2, 108.2) 90.0 (76.0, 104.0), P¼ 0.383 95.7 (81.7, 109.7) 90.0 (76.0, 104.0), P¼ 0.441 97.1 (84.2, 110.1) 82.9 (69.9, 95.8), P¼ 0.276 TXT: 0.138 Group: 0.902
TXT*Group: 0.681
XXIII. Volume 91.7 (75.6, 107.8) 71.7 (55.6, 87.8), P¼ 0.058 88.2 (72.1, 104.3) 80.8 (64.7, 96.9), P¼ 0.477 94.3 (79.4, 109.2) 82.1 (67.2, 97.0), P¼ 0.297 TXT: 0.032 Group: 0.706
TXT*Group: 0.667
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R.E. Miller et al. / Osteoarthritis and Cartilage 18 (2010) 1608e16191614untreated; treatment P¼ 0.087). There was no difference among
groups (group P¼ 0.490).
Gross observation of joints
Upon necropsy, joints and incision areas in all experimental
groups appeared normal by gross examination (Fig. 1), and no
inﬂammation or infection was noted, indicating no adverse immune
reaction to the treatments. Repair cartilage appeared to be moder-
ately to normally attached to surrounding cartilage in all defectswith
no differences between treatments (treatment P¼ 0.299) or groups
(group P¼ 0.541) (Table IV: XIII). Similarly, repair tissue ranged from
normal to slightly-soft compared to surrounding tissue when
assessed for attachment to the subchondral bone, with no differ-
ences between treatments (treatment P¼ 0.192) or groups (group
P¼ 0.970) (Table IV: XIV). Rabbits receiving KLDþ CFþ BMSCs
(group 3) demonstrated mild osteophyte formation, with an
increased score compared to KLD-alone (group 1) (group P¼ 0.029)
(Table IV: VIII). Treated defects in group 3 also had better attachment
to subchondral bone compared to untreated defects in group 3
(P¼ 0.030) (Table IV: XIV). Overall, treated defects had an increased
defect volume ﬁlled (91.4 (82.3, 100.4), treated vs 78.2 (69.1, 87.3),
untreated, treatment P¼ 0.032) and the level of treated defects was
higher than contralateral untreated defects (2.6 (2.3, 3.0), treated;
2.2 (1.8, 2.6), untreated; treatment P¼ 0.050). Untreated defects also
had more muscle wastage at the site of incision (assessed by
circumferential measurement at the proximal aspect of the patella)
(12.9 cm (12.5, 13.2), treated vs 12.7 cm (12.3, 13.0), untreated;
treatment P¼ 0.001), with group 1 and 3 treated defects different
from their respective contralateral controls (Table IV:III; interaction
P¼ 0.032). Treated defects were scored higher in grade of repair
compared to contralateral untreated defects, equivalent to a score of
good (3.0 (2.6, 3.5), treated vs 2.5 (2.0, 2.9), untreated, on a scale of
0e4; treatment P¼ 0.061).re
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1Histologic examinations
Synovial membrane H&E
Evaluation of the synovial membrane by H&E staining showed
some mild intimal hyperplasia and some mild to moderate vascu-
larity and subintimal ﬁbrosis, but there were no differences among
any groups or treatments.Ta
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Assessment of the articular cartilage H&E staining showed that
KLD (group 1) had a higher cumulative histology score compared to
contralateral untreated controls when looking at that group alone
(Table V: XII, P¼ 0.034). Overall, when comparing among groups,
KLD and KLDþ CF (groups 1 and 2) had higher cumulative scores
than KLDþ CFþ BMSCs (group 3) (Table V: XII, group P¼ 0.030).
Defects treated with KLD received the highest score for nature of
predominant tissue in the defect (see Tables III, V: I), which was
similar to ﬁbrocartilage. The other groups and treatments ranged
between 0 and 1, indicating presence of some ﬁbrocartilage and
some non-chondrocytic cells; however, none of the groups or
treatments were signiﬁcantly different (Table V:I, group P¼ 0.749,
treatment P¼ 0.264). Group 3 had signiﬁcantly lower surface
regularity with scores indicative of some ﬁssuring of the surface
(Tables III, V:II, group P¼ 0.005) and more degenerative change in
cartilage surrounding the defect, showing mild to moderate
hypocellularity compared to KLD and KLDþ CF (Tables III, V: VIII,
group P¼ 0.015). Group 2 had more reconstitution of subchondral
R.E. Miller et al. / Osteoarthritis and Cartilage 18 (2010) 1608e1619 1615bone than group 3 (group P¼ 0.030), but all groups were still below
normal subchondral bone levels (Tables III, V: IX); treated defects
trended higher than untreated defects (1.9 (1.5, 2.2) treated; 1.5 (1.1,
1.8) untreated; treatment P¼ 0.074). Group 2 also showed the
highest score for bonding to adjacent cartilage (Table V: V), but no
groups or treatments were signiﬁcantly different (treatment
P¼ 0.161, group P¼ 0.226). Treated defects had increased cellu-
larity (Table III: VI) compared to contralateral untreated defects
(treatment P¼ 0.031) showing normal to slight hypocellularity in
the treated defects repair tissue (1.8 (1.5, 2.0) treated; 1.6 (1.3, 1.8)
untreated); group 3 trended higher than the other groups (2.0 (1.7,
2.3) group 3; 1.5 (1.1, 1.9) groups 1 and 2; group P¼ 0.081).
Articular cartilage SOFG
Defects treated with KLD-alone (group 1) had increased
Safranin-O staining (scores of slight to moderate staining) than theFig. 2. Safranin-O staining. Images showing histological evaluation of representative treatm
pictures were representative of the mean scores and were taken from different animals forcontralateral untreated defects or treated defects in groups 2 and 3,
which had only none to slight staining (Table V: XI, interaction
P¼ 0.011). There was no overall effect of treatment or group on this
measure (treatment P¼ 0.286, group P¼ 0.604). As shown in Fig. 2,
treatment with KLD-alone resulted in greater staining throughout
the repair tissue.
Immunohistochemistry evaluations
Looking at only group 1, defects treated with KLD showed
increased collagen II immunostaining compared to contralateral
untreated defects (Table VI: III, P¼ 0.028); although aggrecan
immunostaining for defects treated with KLD received a score of
2.7, it was not different from the contralateral untreated control
(Table VI:I, P¼ 0.526). This is in contrast to the difference observed
in Safranin-O staining between defects treated with KLD and the
contralateral untreated defects. In group 2, KLDþ CF treatmentent groups and representative contralateral control knees. Treatment and contralateral
KLD and KLDþ CFþ BMSCs, and from the same animal for KLDþ CF. Scale bar¼ 1 mm.
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R.E. Miller et al. / Osteoarthritis and Cartilage 18 (2010) 1608e16191616elicited a tissue with higher aggrecan detected by immunostaining
vs the contralateral untreated control (Table VI:I, P¼ 0.041). In
addition, although defects treated with KLDþ CF received the
highest collagen II immunostaining score of all the groups, 3.4, this
was not different from its contralateral untreated control (Table
VI:III, P¼ 0.110). Comparing all defects, treated defects had more
collagen II (2.9 (2.2, 3.6) treated; 1.6 (0.9, 2.2) untreated; treatment
P¼ 0.001) and increased aggrecan (2.9 (2.3, 3.4) treated; 2.1 (1.6,
2.7) untreated; treatment P¼ 0.056) compared to untreated
defects; there were no differences among groups (group P¼ 0.293).
There were similar levels of collagen I immunostaining found in all
the defects (treatment P¼ 0.471, group P¼ 0.919), consistent with
the observation of mostly ﬁbrocartilage seen in the gross scoring
(Table VI: II). Overall, within the repair tissues, collagen II immu-
nostaining was observed deeper in the sections and collagen I
immunostaining was seen more in the superﬁcial. Aggrecan
immunostaining was noted to have a more generalized distribu-
tion, but more positive staining was seen deeper in the repair
tissue.
Discussion
Treatment of full-thickness articular cartilage defects with the
self-assembling peptide KLD (group 1) markedly improved carti-
lage regeneration, as seen by signiﬁcant increases in cumulative
histology score, Safranin-O staining, and collagen II immunostain-
ing, compared to critically-sized contralateral untreated defects.
KLD has several advantages as a material due to its ability to be
injected arthroscopically into a defect, assemble on contact with
tissue, and promote cartilage regeneration without inducing an
immune response. Adding TGF-b1, dexamethasone, and IGF-1 to
KLD (group 2) resulted in increased aggrecan immunostaining
compared to its contralateral untreated defect, but in general did
not result in any additional beneﬁcial or deleterious effects
compared to KLD-alone (group 1). Motivated by in vitro results
supporting BMSC chondrogenesis33,34,38, we delivered these factors
with allogeneic BMSCs in KLD in vivo (group 3). However, this
treatment resulted in a poorer repair than with KLD or KLDþ CF.
This is similar to other reports of ﬁbrous tissue formation after
BMSC treatment23,24,26, interpreted as a negative result.
In our rabbit model, the presence of a full-thickness defect
allowed bone marrow to inﬁltrate the defect46 and act as a cell
source, similar to abrasion arthroplasty and subchondral bone
microfracture surgical techniques. The positive healing response
seen with KLD treatment (group 1) demonstrates that the scaffold
supports cell migration and further chondrogenesis of these cells in
vivo. The high porosity of this scaffold (w99.6% water content31) is
in agreement with a recent in vivo study in rabbits by Ikeda et al.47
demonstrating that scaffolds with >85% porosity promoted
migration of bone marrow cells into polymer scaffolds and with an
in vitro study by Wang et al.48 demonstrating endothelial cell
migration into several types of self-assembling hydrogels.
Regarding group 2, KLDþ CF treatment, our results raise the
issues of whether the CF dose was appropriate to improve endog-
enous cell response and whether cells migrating into the scaffold in
vivo respond differently to these CFs than in vitro and thereby
require different stimulation. The inclusion of CFs did not show
increased chondrogenesis over KLD-alone (group 1) as determined
by cumulative histology score, Safranin-O, aggrecan, and type II
collagen immunostaining. Similar to these results, Holland et al.13
reported that TGF-b1 and IGF-1 delivered in gelatin microparti-
cles within an acellular oligo(poly(ethylene glycol) fumarate) (OPF)
scaffold resulted in repair no different than in empty defects,
despite positive results in vitro. That study also delivered IGF-1
alone and found that this growth factor alone resulted in
R.E. Miller et al. / Osteoarthritis and Cartilage 18 (2010) 1608e1619 1617a signiﬁcantly improved repair. In addition, other studies have
looked at delivering IGF-1 alone in vivo and have reported similar
positive results4,16. While we did not test the effects of IGF-1 alone
in this study, our results emphasize the need for further under-
standing of the combination of IGF-1 with other CF in vivo in order
to take advantage of its characteristic anabolic properties.
The intra-articularuseof TGF-b1remains controversial due to the
pro-inﬂammatory response by the synovium seen at certain
concentrations. Van der Kraan and van den Berg et al. have studied
the interaction of TGF-b1 with various joint tissues and have shown
that while TGF-b1 can stimulate proteoglycan production in carti-
lage, when it is exposed to synovial tissue, synovial ﬁbrosis can
occur; TGF-b1-induced osteophyte formation is also common18. Mi
et al.17 showed that injection of recombinant adenoviral vector for
hTGF-b1 into the knee joint space through the patellar tendon
(resulting in w8.75 ng TGF-b1) dramatically increased joint
inﬂammation, though thisdose ismore than six-foldhigher thanour
total dose of 1.4 ng. Accordingly, we did not observe these effects
when TGF-b1 was added to the peptide alone (group 2). In contrast,
when TGF-b1 was added in combination with BMSCs (group 3),
osteophyte formation increased, suggesting an interactionof TGF-b1
with these cells was responsible for the increased osteogenesis
rather than the presence of TGF-b1 alone in the joint (group 2). This
ﬁnding is similar to results recently published by Guo et al.27, in
which 600 ng of TGF-b1/mL of hydrogel was used in combination
with BMSCs in an OPF scaffold. Furthermore, we observed a detri-
mental increase in osteophyte formation and distortion of normal
joint anatomy when, in the same rabbit, 1.4 ng TGF-b1þ BMSCs
were placed in one joint and 0.7 ng TGF-b1þ BMSCs in the contra-
lateral joint49. The authors were surprised at this result given the
total body dose of TGF-b1was only 1.5whatwas used in group2 or
group 3 and the cell numbers two-fold greater.While the amount of
TGF-b1 delivered in group 3 of our study was lower than that in the
Mi17 study, and we attempted to deliver TGF-b1 in a controlled
fashion, it is still possible that this TGF-b1 level was too high to
beneﬁcially induce chondrogenesis when combined with BMSCs,
despite the inclusion of dexamethasone, which has been shown to
enhance chondrogenesis compared to TGF-b1 alone9,50. A study by
Fan et al. using only 0.8 ng of TGF-b1 with BMSCs in a gelatin-
chondroitin-hyaluronate tri-copolymer scaffold reported improved
rabbit cartilage defect healing compared to treatment with BMSCs
implanted in a scaffold without TGF-b1. Taken together, these
studies suggest thatwhile the amountof TGF-b1wechose combined
with BMSCs effectively induces chondrogenesis in vitro38, additional
research is needed to determine a successful strategy for optimizing
chondrogenesis of BMSCs in vivo, and interactions with synovial
tissues must be considered.
Due to the often noted ability of cartilage defects in young/skel-
etally immature rabbits to heal well naturally46, we used skeletally
mature rabbits with average age of 11 months and critically-sized
defects in order to test the ability of treatment to improve adult
animal healing. Although full-thickness defects were used, defects
only entered the subchondral/trabecular bone, resulting in contra-
lateral untreated defects that do not heal spontaneously by 12
weeks. These results are similar to other studies using similar-aged
rabbits and defect sizes. A limitation of our model is the lack of
enough tissue to perform direct biochemical assessment in addition
to histological and immunohistochemical measurements in this
study. However, the purpose of the present study was to perform an
initial trial prior to a larger animal study where such additional
measures will be utilized, since ample tissue will be available.
In summary, the self-assembling peptide hydrogel KLD offers
a new material suitable for further testing in a clinically relevant
defect in a large animal. We demonstrated improved ﬁlling of
osteochondral defects and improved cartilage repair, as seen bycumulative histology score, Safranin-O staining, and type II
collagen immunostaining. In this small animal model, the full-
thickness defect provided access to the marrow, similar in concept
to abrasion arthroplasty or spongialization in large animal models
(goat, sheep, horse, human), and suggests that combining KLD with
these techniques may offer an improvement over current practice.
Ongoing studies include the evaluation of KLD in a clinically rele-
vant sized equine defect co-treated with microfracture and sub-
jected to strenuous exercise, compared to defects treated with
microfracture alone.
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